Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 116

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 116
---
 prior to this offering, our executive officers, directors, holders of 5%
or more of our capital stock, and their respective affiliates beneficially owned approximately % of our voting stock. Immediately following the completion of this offering, our executive officers, directors, holders of 5%
or more of our capital stock and their respective affiliates will beneficially hold, in the aggregate, approximately % of our outstanding common stock (assuming no exercise of the underwriters’ option to
purchase additional shares of our common stock, no exercise of outstanding options, and no purchases of shares in this offering). These stockholders, acting together, would be able to significantly influence all matters requiring stockholder
approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This level of
control may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The significant concentration of stock ownership may adversely affect the
trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.

The initial public
offering price will be substantially higher than the pro forma as adjusted net tangible book value per share of our common stock after this offering. Investors purchasing common stock in this offering will pay a price per share that substantially
exceeds the pro forma as adjusted net tangible book value per share after this offering. As a result, investors purchasing common stock in this offering will incur immediate dilution of $ per share, based on an assumed initial public
offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, representing the difference between our pro forma as adjusted net tangible book value per share after giving effect
to this offering and the assumed initial public offering price. Further, investors purchasing common stock in this offering will contribute approximately % of the total amount invested by stockholders since our inception but will own only
approximately % of the shares of common stock outstanding after this offering.

This dilution is due to our investors who purchased
shares prior to this offering having paid substantially less when they purchased their shares than the price offered to the public in this offering. To the extent outstanding options or warrants are exercised, there will be further dil